Press Releases

Date Title and Summary Additional Formats
Toggle Summary Minerva Neurosciences Announces Update for Three Clinical Trials
Company to host conference call at 8:30 a.m. today (dial-in information below)   WALTHAM, Mass. , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS)
View HTML
Toggle Summary Minerva Neurosciences to Host Conference Call and Live Webcast on Tuesday, October 1 at 8:30 AM ET
WALTHAM, Mass. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, will hold a conference call and live audio webcast on October 1, 2019 ,
View HTML
Toggle Summary Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone
WALTHAM, Mass. and SOMERSET , N.Y., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, and Catalent , the leading global
View HTML
Toggle Summary Minerva Neurosciences Reports Second Quarter 2019 Financial Results and Business Updates
During the Second Quarter, Minerva announced several important clinical advancements, including positive top line results from two Phase 2b studies of seltorexant (MIN-202) in major depressive disorder (MDD) and insomnia Patient enrollment progresses in pivotal Phase 3 trial of roluperidone
View HTML
Toggle Summary Minerva Neurosciences to Report Second Quarter 2019 Financial Results and Business Updates on August 5, 2019
Management to host conference call WALTHAM, Mass. , July 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
Toggle Summary Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia
Primary endpoint, defined as Latency to Persistent Sleep (LPS) at Night 1, showed improvement with a p-value ≤0.001 after treatment with 10 and 20 mg doses of seltorexant Key secondary endpoint, defined as Wake After Sleep Onset over first 6 hours (WASO‑6) at Night 1, showed improvement with a
View HTML
Toggle Summary Minerva Neurosciences to Host Live Conference Call and Webcast With Key Opinion Leaders to Discuss Successful Insomnia Trial With Seltorexant
Call scheduled for 8:30 a.m. Eastern Time on June 24 to review results of successful Phase 2b trial showing achievement of primary and secondary endpoints with potential first-in-class specific orexin- 2 receptor antagonist for the treatment of insomnia Key Opinion Leaders, Dr. Thomas Roth and Dr.
View HTML
Toggle Summary Minerva Neurosciences to Present at JMP Securities Life Sciences Conference
WALTHAM, Mass. , June 12, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the JMP Securities
View HTML
Toggle Summary Minerva Neurosciences to Present at Jefferies 2019 Global Healthcare Conference on June 4, 2019
WALTHAM, Mass. , May 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2019
View HTML
Toggle Summary Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs
Potential first-in-class, oral specific orexin- 2 inhibitor demonstrates statistically significant improvement in MADRS scores at 6 weeks compared to placebo Well tolerated, with adverse events similar to or lower than the rate observed in the placebo group Improves depressive symptoms and sleep
View HTML